Home / Resources / Articles / No Insulin Needed? A Major Trial Finds CGM Benefits in an Overlooked Diabetes Group

No Insulin Needed? A Major Trial Finds CGM Benefits in an Overlooked Diabetes Group

Nov 15, 2026
1,666 views
 

Continuous glucose monitoring was once associated mainly with insulin treatment. However, the randomized CONNECT trial challenges that boundary. Published in October 2026, the study suggests that continuous glucose monitoring (CGM) can improve blood sugar control in adults with type 2 diabetes who do not use insulin. Could real-time glucose feedback help more people manage their diabetes?

Table of Contents

  • Why monitoring matters beyond insulin
  • CONNECT trial results
  • How real-time feedback may guide care
  • Coverage barriers and unanswered questions

Why Continuous Glucose Monitoring Matters Beyond Insulin Treatment

Many adults with type 2 diabetes rely on occasional fingerstick checks and A1C tests. Both have value, but each offers only part of the picture. A1C reflects average glucose over roughly three months, while a fingerstick captures one moment. In contrast, CGM reveals patterns after meals, during activity, and overnight.

 

CONNECT tested whether those added insights improve outcomes without insulin treatment. Researchers enrolled 283 adults at 22 U.S. primary care practices. Participants were 21 to 84 years old, with an average starting A1C near 8.8%. About one-third belonged to racial or ethnic minority groups.

Investigators assigned 145 participants to the Dexcom G7 and 138 to routine care. Over 26 weeks, CGM users could see their glucose readings in real time. Meanwhile, controls used conventional monitoring and wore blinded sensors during scheduled assessments. This design tested the value of access to ongoing glucose feedback.

CONNECT Trial Results: Lower A1C and More Time in Range

The CONNECT study published in the New England Journal of Medicine reported a clear difference between groups. Average A1C fell from 8.8% to 7.2% with CGM, compared with 8.7% to 8.0% under routine care. The adjusted between-group difference was 0.9 percentage points, favoring CGM.

Researchers also measured time in range, when glucose stays between 70 and 180 mg/dL. CGM users spent 21 percentage points more time in this range than controls. That equals about five additional hours daily. As a result, the benefits extended beyond an improved A1C average to less exposure to elevated glucose.

Time spent below 70 mg/dL was slightly lower with CGM, and neither group reported severe hypoglycemia events. However, the study lasted only six months. It cannot prove that improved readings prevent long-term complications. For clinical context, see Diabetes in Control's guide to using time in range.

How Real-Time Glucose Feedback May Improve Treatment Decisions

Why might monitoring help someone who does not use insulin? Imagine a patient with an acceptable morning reading but a large glucose rise after dinner. Occasional checks may miss that pattern. With CGM, the patient and clinician can see it and discuss possible changes.

For example, glucose trends can help patients compare meals, movement, and daily routines. Clinicians may use those patterns to discuss medication use, activity, and realistic goals. However, patients also need guidance to avoid overreacting to every reading.

The findings support using CGM to help manage type 2 diabetes in patients who are not taking insulin, alongside established treatments. CGM does not replace metformin, GLP-1 drugs such as Ozempic, or SGLT2 inhibitors such as Jardiance when appropriate. Moreover, CONNECT did not determine which specific behavior changes caused the benefit.

CGM measures glucose in fluid beneath the skin rather than directly in blood. Consequently, readings may differ from fingerstick results when glucose changes quickly. Patients still need access to a blood glucose meter when readings conflict with symptoms. A practical guide to CGM in primary care explains how clinicians can review this information.

CGM Access, Coverage, and Unanswered Questions

The American Diabetes Association's 2026 Standards of Care recommend CGM when it helps diabetes management, including for people who do not use insulin. Therefore, insulin treatment alone need not decide whether clinicians consider a sensor.

Insurance coverage is a separate matter. Under Medicare's current rules, beneficiaries generally must use insulin or have a qualifying history of problematic hypoglycemia. They also need appropriate training and a clinician's order. Consequently, people who might benefit from CGM may still face coverage limits or out-of-pocket costs.

Further research remains important. Dexcom funded CONNECT, making independent replication valuable. The trial also cannot establish whether benefits last for years or reduce heart, kidney, or eye complications. In addition, researchers need to assess quality of life, cost-effectiveness, and whether intermittent monitoring could work as well for some patients.

These findings could help inform broader insurance coverage for continuous glucose monitors among people with type 2 diabetes who do not use insulin. Meanwhile, clinicians should tailor recommendations to each patient's needs, preferences, and ability to use the data.

Conclusion

CONNECT shows that CGM improves A1C and time in range in adults with type 2 diabetes who are not taking insulin. Still, long-term outcomes and costs remain uncertain. Better access should go hand in hand with patient education and individualized care.

FAQs

  • Can continuous glucose monitoring help people with type 2 diabetes who don't use insulin? Yes. CONNECT found better glucose outcomes with CGM than with routine care over 26 weeks.
  • How much did A1C improve? It fell by 1.6 percentage points with CGM and 0.7 points with routine care. The adjusted between-group difference was 0.9 points.
  • Does CGM replace diabetes medication? No. It adds useful feedback but does not replace prescribed treatment.
  • Will Medicare cover CGM without insulin? Sometimes. A qualifying history of problematic hypoglycemia may allow coverage if other requirements are met.
  • Who should ask about CGM? Patients who could benefit from clearer glucose patterns can discuss options with a healthcare professional, including through Healthcare.pro.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.